Jardiance Receives New Heart Failure Indication
August 18, 2021Korsuva Becomes First in a New Class of Drugs to Win FDA Approval
August 23, 2021August 20, 2021 – The U.S. FDA has approved Opdivo® (nivolumab) as an adjuvant treatment for patients who have urothelial carcinoma and are at high risk of recurrence after undergoing radical resection (surgery to remove the cancer).
- Opdivo has multiple indications to treat cancer, including but not limited to lung cancer, kidney cancer, lymphoma, stomach cancer, and liver cancer.
- Recommended dosing is 240mg every two weeks or 480mg every four weeks until disease progression or unacceptable toxicity occur. Opdivo, manufactured by Bristol Myers Squibb, is given by intravenous infusion.
- The FDA first approved the drug in 2014.